SCPH SCPharmaceuticals Inc

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors that day.

A webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Miranda

scPharmaceuticals Inc., 781-301-6869

Investors:

PJ Kelleher

LifeSci Advisors, 617-430-7579



EN
29/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and...

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch